20.05.2010 – 12:53
/K I L L K I L L K I L L -- Roche/
Journalists and other readers should disregard the news release "Phase III Study Showed First-Line Maintenance use of MabThera Doubles Likelihood of People With Follicular Lymphoma Living Without Their Disease Worsening" OTC:RHHVF, issued earlier today. The information contained within this press release should have been embargoed until 23:00BST, May 20th.
CONTACT: Roche Group Media Relations, Phone: +41-61-688-8888,
e-mail:firstname.lastname@example.org, Alexander Klauser, Martina Rupp,
ClaudiaSchmitt, Nina Schwab-Hautzinger
Original content of: Roche Pharmaceuticals, transmitted by news aktuell